H. A. Luchman

发表

Chromatin Blueprint of Glioblastoma Stem Cells Reveals Common Drug Candidates for Distinct Subtypes

S. Weiss, B. Haibe-Kains, M. Lupien, 2018, bioRxiv.

Lactate dehydrogenase A silencing in IDH mutant gliomas.

S. Weiss, J. Cairncross, M. Blough, 2014, Neuro-oncology.

The functional genomic circuitry of human glioblastoma stem cells

S. Weiss, Helen Yu, S. Angers, 2018, bioRxiv.

On-target JAK 2 / STAT 3 inhibition slows disease progression in orthotopic xenografts of human glioblastoma brain tumor stem cells

S. Weiss, J. Cairncross, M. Blough, 2013 .

Rational Drug Design of Targeted and Enzyme Cleavable Vitamin E Analogs as Neoadjuvant to Chemotherapy: In Vitro and In Vivo Evaluation on Reduction of Cardiotoxicity of Doxorubicin

Raghu Pandurangi, H. A. Luchman, Cynthia X. Ma, 2021, bioRxiv.

Developmentally regulated cytoplasmic retention of the transcription factor XMI-ER1 requires sequence in the acidic activation domain.

J. Post, H. A. Luchman, L. Gillespie, 2005, The international journal of biochemistry & cell biology.

Temporally controlled prostate epithelium‐specific gene alterations

F. Jirik, A. Peterson, H. A. Luchman, 2008, Genesis.

Differential nuclear localization of ER1 protein during embryonic development in Xenopus laevis

H. A. Luchman, L. Gillespie, K. Kao, 1999, Mechanisms of Development.

Spontaneous loss of heterozygosity leading to homozygous R132H in a patient-derived IDH1 mutant cell line.

S. Weiss, J. Cairncross, C. Chesnelong, 2013, Neuro-oncology.

SLUG Directs the Precursor State of Human Brain Tumor Stem Cells

S. Weiss, C. Chesnelong, X. Hao, 2019, Cancers.

Precursor States of Brain Tumor Initiating Cell Lines Are Predictive of Survival in Xenografts and Associated with Glioblastoma Subtypes

Steven J. M. Jones, S. Weiss, M. Marra, 2015, Stem cell reports.

Comparative genomic and genetic analysis of glioblastoma-derived brain tumor-initiating cells and their parent tumors.

M. Blough, B. Davis, H. A. Luchman, 2016, Neuro-oncology.

Genome-Wide CRISPR-Cas9 Screens Expose Genetic Vulnerabilities and Mechanisms of Temozolomide Sensitivity in Glioblastoma Stem Cells.

S. Weiss, Helen Yu, S. Angers, 2019, Cell reports.

Live-Cell Imaging Assays to Study Glioblastoma Brain Tumor Stem Cell Migration and Invasion

S. Weiss, C. Chesnelong, H. A. Luchman, 2018, Journal of visualized experiments : JoVE.

Dual mTORC1/2 Blockade Inhibits Glioblastoma Brain Tumor Initiating Cells In Vitro and In Vivo and Synergizes with Temozolomide to Increase Orthotopic Xenograft Survival

S. Weiss, J. Cairncross, H. A. Luchman, 2014, Clinical Cancer Research.

Cancer Therapy : Preclinical Dual mTORC 1 / 2 Blockade Inhibits Glioblastoma Brain Tumor Initiating Cells In Vitro and In Vivo and Synergizes with Temozolomide to Increase Orthotopic Xenograft Survival

S. Weiss, J. Cairncross, H. A. Luchman, 2014 .

On-target JAK2/STAT3 inhibition slows disease progression in orthotopic xenografts of human glioblastoma brain tumor stem cells.

S. Weiss, J. Cairncross, M. Blough, 2013, Neuro-oncology.

Control of glioblastoma tumorigenesis by feed-forward cytokine signaling

M. Rudnicki, T. Perkins, S. Weiss, 2016, Nature Neuroscience.

2-Hydroxyglutarate-Mediated Autophagy of the Endoplasmic Reticulum Leads to an Unusual Downregulation of Phospholipid Biosynthesis in Mutant IDH1 Gliomas.

J. Cairncross, J. L. Izquierdo-García, R. Pieper, 2018, Cancer research.

Clonal expansion and epigenetic reprogramming following deletion or amplification of mutant IDH1

Steven J. M. Jones, Susan M. Chang, A. Olshen, 2017, Proceedings of the National Academy of Sciences.

Hyperpolarized 13C MR imaging detects no lactate production in mutant IDH1 gliomas: Implications for diagnosis and response monitoring

J. Cairncross, C. Najac, M. Blough, 2016, NeuroImage: Clinical.

An in vivo patient-derived model of endogenous IDH1-mutant glioma.

S. Weiss, J. Cairncross, A. Weljie, 2012, Neuro-oncology.

Gradient of Developmental and Injury Response transcriptional states defines functional vulnerabilities underpinning glioblastoma heterogeneity

Gary D Bader, Richard A. Moore, Trevor J Pugh, 2021, Nature Cancer.

The Pace of Prostatic Intraepithelial Neoplasia Development Is Determined by the Timing of Pten Tumor Suppressor Gene Excision

F. Jirik, A. Peterson, H. A. Luchman, 2008, PloS one.

PD-1 independent of PD-L1 ligation promotes glioblastoma growth through the NFκB pathway

V. Yong, C. Hao, P. Bose, 2021, Science advances.

Early Noninvasive Metabolic Biomarkers of Mutant IDH Inhibition in Glioma

J. Costello, C. Najac, R. Pieper, 2021, Metabolites.

Comprehensive genomic profiling of glioblastoma tumors, BTICs, and xenografts reveals stability and adaptation to growth environments

Steven J. M. Jones, Richard A. Moore, S. Weiss, 2019, Proceedings of the National Academy of Sciences.

Novel MSH6 Mutations in Treatment-Naïve Glioblastoma and Anaplastic Oligodendroglioma Contribute to Temozolomide Resistance Independently of MGMT Promoter Methylation

S. Weiss, J. Cairncross, S. Robbins, 2014, Clinical Cancer Research.

Mgmt deficiency alters the in vivo mutational spectrum of tissues exposed to the tobacco carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK).

F. Jirik, L. Peterson, H. A. Luchman, 2008, Carcinogenesis.

Non-invasive assessment of telomere maintenance mechanisms in brain tumors

P. Larson, J. Costello, R. Pieper, 2021, Nature Communications.

Characterization of the expression and function of the early response 1 gene in Xenopus laevis embryonic development

H. A. Luchman, 2002 .

A phase I study of vistusertib (dual mTORC1/2 inhibitor) in patients with previously treated glioblastoma multiforme: a CCTG study

S. Weiss, W. Mason, L. Seymour, 2019, Investigational New Drugs.

EXPERIMENTAL THERAPEUTICS AND PHARMACOLOGY

Tina N. Davis, Forrest M Kievit, Atique U. Ahmed, 2013 .

The JAK2/STAT3 inhibitor pacritinib effectively inhibits patient-derived GBM brain tumor initiating cells in vitro and when used in combination with temozolomide increases survival in an orthotopic xenograft model

S. Weiss, H. A. Luchman, A. Aman, 2017, PloS one.

IDH1 Mutation Induces Reprogramming of Pyruvate Metabolism.

S. Weiss, J. Cairncross, J. L. Izquierdo-García, 2015, Cancer research.

Prostate epithelium-specific deletion of the selenocysteine tRNA gene Trsp leads to early onset intraepithelial neoplasia.

B. Carlson, F. Jirik, T. Bismar, 2014, The American journal of pathology.

Metabolic imaging detects elevated glucose flux through the pentose phosphate pathway associated with TERT expression in low-grade gliomas.

P. Larson, J. Costello, R. Pieper, 2021, Neuro-oncology.

Brain Tumor Stem Cell Dependence on Glutaminase Reveals a Metabolic Vulnerability through the Amino Acid Deprivation Response Pathway

Trevor J Pugh, S. Weiss, T. Pugh, 2020, Cancer Research.

Mutant IDH1 gliomas downregulate phosphocholine and phosphoethanolamine synthesis in a 2-hydroxyglutarate-dependent manner

J. L. Izquierdo-García, R. Pieper, J. Phillips, 2018, Cancer & metabolism.

EGFR blockade in GBM brain tumor stem cells synergizes with JAK2/STAT3 pathway inhibition to abrogate compensatory mechanisms in vitro and in vivo

S. Weiss, X. Hao, H. A. Luchman, 2020, Neuro-oncology advances.

cDNA Cloning of a Novel, Developmentally Regulated Immediate Early Gene Activated by Fibroblast Growth Factor and Encoding a Nuclear Protein*

H. A. Luchman, L. Gillespie, P. Ryan, 1997, The Journal of Biological Chemistry.

Mutational-reporter transgenes rescued from mice lacking either Mgmt, or both Mgmt and Msh6 suggest that O6-alkylguanine-induced miscoding does not contribute to the spontaneous mutational spectrum

L. Samson, F. Jirik, H. A. Luchman, 2004, Oncogene.

Elevated mutant frequencies and predominance of G:C to A:T transition mutations in Msh6−/− small intestinal epithelium

Á. Baross, W. Edelmann, F. Jirik, 2002, Oncogene.

Identification and Characterization of AES-135, a Hydroxamic Acid-Based HDAC Inhibitor That Prolongs Survival in an Orthotopic Mouse Model of Pancreatic Cancer.

S. Weiss, M. Geletu, M. Deininger, 2019, Journal of medicinal chemistry.

Potent Targeting of the STAT3 Protein in Brain Cancer Stem Cells: A Promising Route for Treating Glioblastoma.

Kagan Kerman, David R Kaplan, Samuel Weiss, 2013, ACS medicinal chemistry letters.

Rational Drug Design of Targeted and Enzyme-Cleavable Vitamin E Analogs as a Neoadjuvant to Chemotherapy: In Vitro and In Vivo Evaluation on Reduction of the Cardiotoxicity Side Effect of Doxorubicin.

Raghu Pandurangi, M. Forrest, H. A. Luchman, 2023, ACS pharmacology & translational science.

DNA hypermethylation and 1p Loss silence NHE‐1 in oligodendroglioma

S. Weiss, M. Marra, J. Cairncross, 2012, Annals of neurology.

Epigenetic and molecular coordination between HDAC2 and SMAD3-SKI regulates essential brain tumour stem cell characteristics

S. Weiss, X. Hao, R. Hassam, 2023, Nature communications.

Dual mTORC1/2 Blockade Inhibits Glioblastoma Brain Tumor Initiating Cells In Vitro and In Vivo and Synergizes with Temozolomide to Increase Orthotopic Xenograft Survival

S. Weiss, J. Cairncross, H. A. Luchman, 2014, Clinical Cancer Research.

BI-907828, a novel potent MDM2 inhibitor, inhibits GBM brain tumor stem cells in vitro and prolongs survival in orthotopic xenograft mouse models.

D. Rudolph, X. Hao, H. A. Luchman, 2022, Neuro-oncology.

On-target JAK2/STAT3 inhibition slows disease progression in orthotopic xenografts of human glioblastoma brain tumor stem cells.

S. Weiss, J. Cairncross, M. Blough, 2013, Neuro-oncology.